394248-99-8

Usage

Properties

It is a tertiary amine.
It has a piperazine ring.
It has a carboxylic acid group.
It has a 4-(2-methoxy-4-nitrophenyl) group.
It has a 1,1-dimethylethyl ester group.

Specific content

It is commonly used as a reagent in organic synthesis.
It is used in medicinal chemistry and pharmaceutical research as a precursor for the synthesis of various drugs and pharmaceuticals.
It is used as a building block in the production of other organic compounds.
It can be used as a catalyst in certain chemical reactions.
It has a variety of potential applications in the field of chemistry and pharmaceuticals.

Upstream product

• 170912-81-9 1-(2-methoxy-4-nitro-phenyl)-piperazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 13120-77-9 2-methyl-5-nitroanisole 
• 454-16-0 1-fluoro-2-methoxy-4-nitrobenzene 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1433823-88-1 1-(4-nitrophenyl)-4-(oxetan-3-yl)piperazine 
• 170912-81-9 1-(2-methoxy-4-nitro-phenyl)-piperazine 
• 1395030-33-7 4-(4-(oxetan-3-yl)piperazin-1-yl)benzenamine 
• 835633-78-8 4-(4-isopropylpiperazin-1-yl)-3-methoxyaniline 
• 394249-01-5 4-[4-(4-cyclohexyl-benzoylamino)-2-methoxy-phenyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 394249-00-4 4-(4-amino-2-methoxyphenyl)piperazine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS

Provided are compounds of Formula (I) which can be used as Syk inhibitors and potently as therapeutic agents against diseases mediated by Syk.

Discovery of benzo[d]oxazole derivatives as the potent type-I FLT3-ITD inhibitors

Fms-like tyrosine kinase 3 (FLT3) has been considered as a potential drug target for the treatment of acute myeloid leukemia (AML), because of its high and aberrant expression in AML patients, especially the patients with FLT3-ITD mutation. Initiating from a hit compound (IC50: 500 nM against FLT3-ITD), a series of compounds were designed and synthesized based on benzo[d]oxazole-2-amine scaffold to discover new potent FLT3-ITD inhibitors. During the medicinal chemistry works, flexible molecular docking was used to provide design rationale and study the binding modes of the target compounds. Through the mixed SAR exploration based on the enzymatic and cellular activities, compound T24 was identified with potent FLT3-ITD inhibitory (IC50: 0.41 nM) and anti-proliferative (IC50: 0.037 μM against MV4-11 cells) activities. And the binding mode of T24 with “DFG-in” FLT3 was simulated by a 20-ns molecular dynamics run, providing some insights into further medicinal chemistry efforts toward novel FLT3 inhibitors in AML therapy.

Pyrrolopyrimidine compound, pharmaceutical composition containing thereof, and preparation method and applications

The invention relates to a pyrrolopyrimidine compound represented by formula I, a pharmaceutical composition containing thereof, and a preparation method and applications in preventing or treating Weel protein kinase related diseases.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

Discovery of potent and stable conformationally constrained analogues of the MCH R1 antagonist SB-568849

A strategy of systematically targeting more rigid analogues of the known MCH R1 receptor antagonist, SB-568849, serendipitously uncovered a binding mode accessible to N-aryl-phthalimide ligands. Optimisation to improve the stability of this compound class led to the discovery of novel N-aryl-quinazolinones, benzotriazinones and thienopyrimidinones as selective ligands with good affinity for human melanin-concentrating hormone receptor 1.